Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.32 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.32 |
| ▸ | GYS1 | P13807 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213388 | 0.88 | TSHR (0.41) | CYP2C9 | |
| SCHEMBL2804576 | 0.82 | CYP2C9 (0.40) | PTGDR2CYP2C9 | |
| SCHEMBL3456655 | 0.81 | ADORA1 (0.43) | CXCR2PTGDR2HDAC6 | |
| SCHEMBL3456353 | 0.81 | PTGDR2 (0.39) | CXCR2PTGDR2HDAC6 | |
| SCHEMBL3456383 | 0.80 | GLA (0.46) | PTGDR2 | |
| SCHEMBL3456716 | 0.79 | PTGDR2 (0.39) | CXCR2PTGDR2AKR1B1 | |
| SCHEMBL3456048 | 0.79 | PTGDR2 (0.37) | CXCR2PTGDR2HDAC6CYP2C9 | |
| SCHEMBL3456552 | 0.78 | ALDH1A1 (0.39) | CXCR2PTGDR2HDAC6PLA2G7 | |
| SCHEMBL6359581 | 0.77 | PTGDR2 (0.38) | CXCR2PTGDR2AKR1B1 | |
| SCHEMBL3456604 | 0.77 | PTGDR2 (0.38) | CXCR2PTGDR2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258688-B1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM LTD (GB) | 2012-11-21 | — | — | EP | disclosed |
| EP-2258688-A1 | Pyridinone derivatives for treatment of atherosclerosis | SmithKline Beecham Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | US | disclosed |
| US-20040063753-A1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLA2G7, PLA2G4B | CXCR2 3318/4885PTGDR2 167/4885HSP90AA1 4470/4885 |
| US-20040063753-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLPBP, PLAA | CXCR2 3185/4885PTGDR2 175/4885HSP90AA1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.